Horton E S, Whitehouse F, Ghazzi M N, Venable T C, Whitcomb R W
Joslin Diabetes Center, Boston, Massachusetts, USA.
Diabetes Care. 1998 Sep;21(9):1462-9. doi: 10.2337/diacare.21.9.1462.
To determine if the combination of troglitazone (a peroxisome proliferator-activated receptor-gamma activator) and sulfonylurea will provide efficacy not attainable by either medication alone.
There were 552 patients inadequately controlled on maximum doses of sulfonylurea who participated in a 52-week randomized active-controlled multicenter study. Patients were randomized to micronized glyburide 12 mg q.d. (G12); troglitazone monotherapy 200, 400, or 600 mg q.d. (T200, T400, T600); or combined troglitazone and glyburide q.d. (T200/G12, T400/G12, T600/G12). Efficacy measures included HbA1c, fasting serum glucose (FSG), insulin, and C-peptide. Effects on lipids and safety were also assessed.
Patients on T600/G12 had significantly lower mean (+/- SEM) FSG (9.3 +/- 0.4 mmol/l; 167.4 +/- 6.6 mg/dl) compared with control subjects (13.7 +/- 0.4 mmol/l; 246.5 +/- 6.8 mg/dl; P < 0.0001) and significantly lower mean HbA1c (7.79 +/- 0.2 vs. 10.58 +/- 0.18%, P < 0.0001). Significant dose-related decreases were also seen with T200/G12 and T400/G12. Among patients on T600/G12, 60% achieved HbA1c < or =8%, 42% achieved HbA1c < or =7%, and 40% achieved FSG < or =7.8 mmol/l (140 mg/dl). Fasting insulin and C-peptide decreased with all treatments. Overall, triglycerides and free fatty acids decreased, whereas HDL cholesterol increased. LDL cholesterol increased slightly, with no change in apolipoprotein B. Adverse events were similar across treatments. Hypoglycemia occurred in 3% of T600/G 12 patients compared with <1% on G12 or troglitazone monotherapy
Patients with type 2 diabetes inadequately controlled on sulfonylurea can be effectively managed with a combination of troglitazone and sulfonylurea that is safe, well tolerated, and represents a new approach to achieving the glycemic targets recommended by the American Diabetes Association.
确定曲格列酮(一种过氧化物酶体增殖物激活受体γ激动剂)与磺脲类药物联合使用是否能产生单独使用任一药物无法达到的疗效。
552例接受最大剂量磺脲类药物治疗但血糖控制不佳的患者参与了一项为期52周的随机、活性对照、多中心研究。患者被随机分为每日服用12毫克微粒化格列本脲组(G12);每日服用200、400或600毫克曲格列酮单药治疗组(T200、T400、T600);或每日联合使用曲格列酮和格列本脲组(T200/G12、T400/G12、T600/G12)。疗效指标包括糖化血红蛋白(HbA1c)、空腹血糖(FSG)、胰岛素和C肽。还评估了对血脂的影响和安全性。
与对照组相比,T600/G12组患者的平均(±标准误)空腹血糖显著降低(9.3±0.4毫摩尔/升;167.4±6.6毫克/分升),对照组为(13.7±0.4毫摩尔/升;246.5±6.8毫克/分升;P<0.0001),平均糖化血红蛋白也显著降低(7.79±0.2%对10.58±0.18%,P<0.0001)。T200/G12和T400/G12组也出现了显著的剂量相关降低。在T600/G12组患者中,60%的患者糖化血红蛋白≤8%,42%的患者糖化血红蛋白≤7%,40%的患者空腹血糖≤7.8毫摩尔/升(140毫克/分升)。所有治疗均使空腹胰岛素和C肽降低。总体而言,甘油三酯和游离脂肪酸降低,而高密度脂蛋白胆固醇升高。低密度脂蛋白胆固醇略有升高,载脂蛋白B无变化。各治疗组的不良事件相似。T600/G12组3%的患者发生低血糖,而G12组或曲格列酮单药治疗组<1%。
对于接受磺脲类药物治疗但血糖控制不佳的2型糖尿病患者,曲格列酮与磺脲类药物联合使用可有效控制病情,安全且耐受性良好,是实现美国糖尿病协会推荐的血糖目标的一种新方法。